08:48 AM EDT, 08/29/2024 (MT Newswires) -- Gain Therapeutics ( GANX ) said Thursday that a review of unblinded data from a phase 1 study of GT-02287 to treat Parkinson's disease confirmed that the drug candidate is safe and generally well tolerated.

The company said it expects to begin the phase 1b study in Q4 and present the results middle of next year.

Shares of Gain Therapeutics ( GANX ) were down more than 5% in recent premarket activity.

Price: 1.2600, Change: -0.07, Percent Change: -5.26